Label-Free Quantification of Anti-TNF-α in Patients Treated with Adalimumab Using an Optical Biosensor

This study describes the development of an immunosensory label-free quantification methodology based on surface plasmon resonance (SPR) and its applicability in measuring/evaluating therapeutic drug monitoring (TDM) of anti-TNF-α monoclonal antibody (adalimumab) in rheumatoid arthritis (RA) patients. The experimental parameters evaluated in this study were immobilising ligands by pre-concentration assays, sensor surface regeneration, ascertaining the method’s sensitivity and correlating the results from quantifying plasma samples by ELISA immunoassay. The results showed that TNF-α quantification values (in RU) were significantly different when comparing patients (~50–250 RU) to controls (~10–20 RU). Likewise, there was 0.97 correlation for patients and 0.91 for healthy volunteers using SPR and ELISA comparison methodologies. SPR immunosensory detection provided a precise, sensitive strategy, along with real-time determination, for quantifying adalimumab, having great potential for clinical routine regarding TDM.

[1]  W Wang,et al.  Monoclonal Antibody Pharmacokinetics and Pharmacodynamics , 2008, Clinical pharmacology and therapeutics.

[2]  K. Bendtzen,et al.  Enzyme Immunoassays and Radioimmunoassays for Quantification of Anti‐TNF Biopharmaceuticals and Anti‐Drug Antibodies , 2011 .

[3]  Jules Beekwilder,et al.  Antibody orientation on biosensor surfaces: a minireview. , 2013, The Analyst.

[4]  B. Dijkmans,et al.  Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. , 2011, JAMA.

[5]  Edward Wells,et al.  Unique challenges of providing bioanalytical support for biological therapeutic pharmacokinetic programs. , 2011, Bioanalysis.

[6]  Pedro Estrela,et al.  Introduction to biosensors , 2016, Essays in biochemistry.

[7]  Uni Wong,et al.  Primary and secondary nonresponse to infliximab: mechanisms and countermeasures , 2017, Expert opinion on drug metabolism & toxicology.

[8]  H. Seymour,et al.  Anti-TNF agents for rheumatoid arthritis. , 2001, British journal of clinical pharmacology.

[9]  Theo Rispens,et al.  Cross-reactive and pre-existing antibodies to therapeutic antibodies—Effects on treatment and immunogenicity , 2015, mAbs.

[10]  J. Burke,et al.  An evaluation of the potential for drug–drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma , 2014, Cancer Chemotherapy and Pharmacology.

[11]  D. Gladman,et al.  The challenge of indication extrapolation for infliximab biosimilars. , 2014, Biologicals : journal of the International Association of Biological Standardization.

[12]  U. Jönsson,et al.  Real-time biospecific interaction analysis , 1992 .

[13]  T. van Gelder,et al.  Comparison of Three Assays to Quantify Infliximab, Adalimumab, and Etanercept Serum Concentrations , 2016, Therapeutic drug monitoring.

[14]  Thomas Singer,et al.  The safety and side effects of monoclonal antibodies , 2010, Nature Reviews Drug Discovery.

[15]  R. Hansen,et al.  Antibody pharmacokinetics and pharmacodynamics. , 2004, Journal of pharmaceutical sciences.

[16]  D. O'Shannessy,et al.  Immobilization chemistries suitable for use in the BIAcore surface plasmon resonance detector. , 1992, Analytical biochemistry.

[17]  S. Taylor-Phillips,et al.  Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn's disease: , 2016, Health technology assessment.

[18]  J. Segura,et al.  Surface plasmon resonance immuno assays - A perspective. , 2009, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[19]  Cynna Selvy,et al.  Clinical Laboratory Improvement Amendments (CLIA) , 2015 .

[20]  M. Caminati,et al.  Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience , 2016, BMC Pulmonary Medicine.

[21]  R Thorpe,et al.  Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals. , 2003, Journal of immunological methods.

[22]  R. Eliakim,et al.  Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[23]  S. Vermeire,et al.  Generation and characterization of a unique panel of anti-adalimumab specific antibodies and their application in therapeutic drug monitoring assays. , 2016, Journal of pharmaceutical and biomedical analysis.

[24]  A. Kamath,et al.  Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies. , 2016, Drug discovery today. Technologies.

[25]  J. Švitel,et al.  Optical biosensors , 2016, Essays in biochemistry.

[26]  J. Madan,et al.  Accurate diagnosis of latent tuberculosis in children, people who are immunocompromised or at risk from immunosuppression and recent arrivals from countries with a high incidence of tuberculosis: systematic review and economic evaluation. , 2016, Health technology assessment.

[27]  M. Hämäläinen,et al.  Increased sensitivity of SPR assays in plasma through efficient parallel assay optimization. , 2013, Journal of pharmaceutical and biomedical analysis.

[28]  A. Matucci,et al.  Anti‐infliximab IgE and non‐IgE antibodies and induction of infusion‐related severe anaphylactic reactions , 2010, Allergy.

[29]  O. Lequin,et al.  Antibody Recognition in multiple sclerosis and rett syndrome using a collection of linear and cyclic N‐glucosylated antigenic probes , 2015, Biopolymers.

[30]  A. Papini,et al.  Surface plasmon resonance-based methodology for anti-adalimumab antibody identification and kinetic characterization , 2015, Analytical and Bioanalytical Chemistry.

[31]  M. Wing.  Monoclonal Antibody First Dose Cytokine Release Syndromes–Mechanisms and Prediction , 2008, Journal of immunotoxicology.

[32]  D. Mould,et al.  Anti‐TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics‐Based Dosing Paradigms , 2012, Clinical pharmacology and therapeutics.

[33]  D. Bonney,et al.  Rituximab-induced Cytokine Storm in the Absence of Overt Lymphoproliferative Disease , 2016, Journal of pediatric hematology/oncology.

[34]  J. Schmier,et al.  Costs of Providing Infusion Therapy for Rheumatoid Arthritis in a Hospital-based Infusion Center Setting. , 2017, Clinical therapeutics.

[35]  L. Brunsveld,et al.  Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits , 2016, Clinical chemistry and laboratory medicine.

[36]  P. V. van Riel,et al.  Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis , 2008, Annals of the rheumatic diseases.

[37]  R. Ravasio,et al.  Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate , 2016, Advances in Therapy.

[38]  M Ohlin,et al.  Real Time Analysis of Antibody‐Antigen Reaction Kinetics , 1992, Scandinavian journal of immunology.

[39]  A. Matucci,et al.  Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management , 2011, Current opinion in allergy and clinical immunology.

[40]  S. Vermeire,et al.  Development and validation of an optical biosensor for rapid monitoring of adalimumab in serum of patients with Crohn's disease. , 2018, Drug testing and analysis.

[41]  S. Nadler,et al.  Immunogenicity to Biotherapeutics – The Role of Anti-drug Immune Complexes , 2016, Front. Immunol..

[42]  G. Paintaud,et al.  Pharmacokinetics and concentration–effect relationships of therapeutic monoclonal antibodies and fusion proteins , 2005, Expert opinion on biological therapy.

[43]  Suprava Patel,et al.  Biosensors in Health Care: The Milestones Achieved in Their Development towards Lab-on-Chip-Analysis , 2016, Biochemistry research international.

[44]  J. Homola,et al.  Surface Plasmon Resonance (SPR) Sensors , 2006 .

[45]  Amarnath Sharma,et al.  Therapeutic protein-drug interactions: plausible mechanisms and assessment strategies , 2016, Expert opinion on drug metabolism & toxicology.

[46]  A. Matucci,et al.  An overview on safety of monoclonal antibodies , 2016, Current opinion in allergy and clinical immunology.

[47]  B. Dijkmans,et al.  Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[48]  Troy E. Barger,et al.  The development and validation of a sensitive, dual-flow cell, SPR-based biosensor immunoassay for the detection, semi-quantitation, and characterization of antibodies to darbepoetin alfa and epoetin alfa in human serum. , 2009, Journal of pharmaceutical and biomedical analysis.

[49]  T. Takeuchi,et al.  Targeted antibody therapy and relevant novel biomarkers for precision medicine for rheumatoid arthritis , 2017, International immunology.

[50]  K. Seitz,et al.  Pharmacokinetic Drug‐Drug Interaction Potentials for Therapeutic Monoclonal Antibodies: Reality Check , 2007, Journal of clinical pharmacology.

[51]  P. Parren,et al.  Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange , 2007, Science.

[52]  Maria Longauer Banholzer,et al.  Clinical development methodology for infusion-related reactions with monoclonal antibodies , 2015, Clinical & translational immunology.

[53]  K. Bendtzen,et al.  Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. , 2007, Rheumatology.

[54]  P. V. D. Merwe.  Surface plasmon resonance , 2002 .

[55]  English Only,et al.  GUIDELINES ON EVALUATION OF SIMILAR BIOTHERAPEUTIC PRODUCTS (SBPs) , 2009 .

[56]  K. Andersson,et al.  Exploring buffer space for molecular interactions , 1999, Journal of molecular recognition : JMR.

[57]  George Scott,et al.  Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. , 2004, Journal of immunological methods.

[58]  S. Vermeire,et al.  Fiber optic-SPR platform for fast and sensitive infliximab detection in serum of inflammatory bowel disease patients. , 2016, Biosensors & bioelectronics.

[59]  Jeho Park,et al.  Surface Plasmon Resonance: A Versatile Technique for Biosensor Applications , 2015, Sensors.

[60]  Saileta Prabhu,et al.  Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development? , 2012, Expert opinion on drug metabolism & toxicology.

[61]  K. Bendtzen,et al.  Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. , 2006, Arthritis and rheumatism.

[62]  Nicki Panoskaltsis,et al.  Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. , 2006, The New England journal of medicine.

[63]  D. Mytych,et al.  The Use of Surface Plasmon Resonance for the Detection and Characterization of Antibodies , 2011 .

[64]  Sehyun Shin,et al.  Analysis of Surface Plasmon Resonance Curves with a Novel Sigmoid-Asymmetric Fitting Algorithm , 2015, Sensors.

[65]  K. Bendtzen,et al.  Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events , 2017, Expert opinion on drug metabolism & toxicology.

[66]  A. Barton,et al.  High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort , 2016, Annals of the rheumatic diseases.

[67]  Morvarid Akhavan Rezaei,et al.  Wide dynamic range of surface‐plasmon‐resonance‐based assay for hepatitis B surface antigen antibody optimal detection in comparison with ELISA , 2017, Biotechnology and applied biochemistry.

[68]  X. Mariette,et al.  Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective , 2012, Annals of the rheumatic diseases.

[69]  A. Hirschfelder.  THE UNITED STATES PHARMACOPEIAL CONVENTION , 1930 .

[70]  J. M. González,et al.  Real-time quantification of proteins secreted by artificial connective tissue made from uni- or multidirectional collagen I scaffolds and oral mucosa fibroblasts. , 2014, Analytical chemistry.